Xvivo Perfusion AB 2022 AR2
The report highlights XVIVO Perfusion AB's performance in 2022, achieving record sales of SEK 415 million with 30 percent organic growth. Key milestones included receiving US FDA 510(k) clearance for Kidney Assist Transport and EU MDR certification for its entire abdominal product portfolio. The company also completed the acquisition of its Italian distributor's machine and perfusion business, now XVIVO S.r.l., and appointed Christoffer Rosenblad as the new CEO. In sustainability, XVIVO conducted its first comprehensive materiality analysis to identify key ESG focus areas and carried out its first employee survey.
Company: Xvivo Perfusion AB
Sector: Health Care
Country: Sweden
Year: 2022
Type: AR2
Pages: 126
Xvivo Perfusion AB
Annual Report
The report highlights XVIVO Perfusion AB's performance in 2022, achieving record sales of SEK 415 million with 30 percent organic growth. Key milestones included receiving US FDA 510(k) clearance for Kidney Assist Transport and EU MDR certification for its entire abdominal product portfolio. The company also completed the acquisition of its Italian distributor's machine and perfusion business, now XVIVO S.r.l., and appointed Christoffer Rosenblad as the new CEO. In sustainability, XVIVO conducted its first comprehensive materiality analysis to identify key ESG focus areas and carried out its first employee survey.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities
Employees